DRM is a subgroup of myofibrillar myopathy caused by mutations in desmin, CryAB and other proteins that interact with the intermediate filaments. The pathology is characterized by myofibril disruption that appears to initiate at the Z-disk. Dislocation and aggregation of membranous organelles is observed as well as the accumulation of the mutant, misfolded desmin and/or CryAB into insoluble aggregates, which gradually increase in the cytoplasm and are thought to eventually result in cell death.
1–3 We previously showed that these aggregates may be classified as aggresomes, whose accumulation is often associated with neurodegenerative diseases caused by protein misfolding or unfolding.
8 Our studies showed that the aggresomes present in the cardiomyocytes contain large concentrations of a toxic amyloid oligomer, which is typically found in many of the amyloid-based neurodegenerative diseases. The data thus link these cardiomyopathies to a broad class of amyloid-based neurodegenerative disease and offer potential insight into the mechanistic bases for the cardiac pathology that eventually results in dilation and death by heart failure.
5A loss of desmin or CryAB function has been thought to be an underlying cause for the development of cardiomyopathy and heart failure in DRM patients due to either the inability of the mutant desmin to maintain cytoskeletal integrity or by the loss by CryAB’s chaperone function, which would subsequently lead to desmin misfolding and eventual formation of the characteristic aggregates. Although loss of function may indeed contribute to the pathology, it cannot explain it completely, as we have noted a relatively benign cardiac phenotype, compared to the CryAB
R120G animals, in homozygous CryAB knockout mice (Maloyan and Robbins, unpublished observations). We think it likely that CryAB
R120G expression leads to a multi-focal pathology. There appears to be physical and mechanical repercussions of CryAB
R120G expression, probably due to the development of the small protein aggregates. Viral transfection into adult rat myocytes, show that the acute effects of CryAB
R120G expression result in significant deficits in both peak shortening and maximum departure velocity with irregular contraction when pacing is increased to 2 Hz (). In addition to the altered cardiomyocyte mechanics in , we showed previously that in transfected cardiomyocytes amyloid oligomer was present within 48–60 hours post-transfection,
8 and in the CryAB
R120G mice as soon as 2–3 days after the transgene is activated (Robbins, unpublished data). However, even in the intensely studied neurodegenerative disease processes thought to be due to amyloid oligomer toxicity, the exact sequence of events leading from amyloid formation to cell death is unknown. Several potentially damaging pathways are activated, including oxidative stress and mitochondrial dysfunction.
15–17 Recently, a direct linkage between β-amyloid and the mitochondria was defined, with β-amyloid binding to the mitochondrial protein Aβ alcohol dehydrogenase.
18The data in this study further underscore the parallels between CryAB
R120G cardiomyopathy and the amyloid-based neurodegenerative pathologies, as mitochondrial dysfunction appears to be an early event in the cardiac pathology, appearing by 6–8 weeks and before any overt changes in organ function can be detected. The biochemical, functional and structural alterations resulted in a significantly compromised Pcr/ATP ratio in early adulthood () before overt functional deficits present. A number of processes could lead to early involvement of the mitochondria. Mitochondria are held in position and can be transported in the cytoplasm through their interactions with cytoskeletal components such as the microtubules and intermediate filaments.
19 We have noted that disruption of the desmin network rapidly leads to alterations in mitochondrial positioning and structure,
5 and similar observations have been made in striated muscle derived from the desmin knockout mice, with severe mitochondrial deficits presenting in both heart and skeletal muscle.
9,13 We hypothesize that disturbance of the tight juxtaposition of the mitochondria over the interior of the sarcomere results in alterations in cellular metabolism. Our data are consistent with CryAB
R120G specifically associating with mitochondria through VDAC interaction early in the pathogenic process. The significance of the preferential association of CryAB
R120G versus the normal protein with VDAC is unclear but raises the possibility that CryAB
R120G may have a direct impact on either VDAC or a mitochondrial protein associated with the PTP. What is clear is that mitochondrial dysfunction is one of the earliest detectable events in the development of R120G-mediated cardiomyopathy and appears to play a major role in the developing pathology. As early as 6 weeks there is a significant reduction in complex I activity and mitochondrial respiration is significantly compromised. Mitochondrial permeability transition is clearly affected in CryAB
R120G transfected cardiomyocytes and precedes the increased levels of apoptotic markers.
The connections between amyloid deposition, mitochondrial dysfunction and cell degeneration and death remain contentious. However, there are increasing data linking amyloidogenic proteins to mitochondrial toxicity. The exposure of isolated brain mitochondria to β-amyloid causes a decrease in mitochondrial enzyme activity, respiration and membrane potential.
20 β-amyloid can activate PTP opening, resulting in mitochondrial swelling,
21 a result consistent with our observations. Impaired function of complex I has also been linked to the development of Parkinson’s and Alzheimer’s diseases,
17,22,23 and in Down’s syndrome there are reduced levels of complex I in the cerebellum.
24 In Parkinson’s disease, the proteins parkin and α-synuclein, which are components of the abnormal aggregates (Lewy bodies) found in patient neurons, bind to one another in vitro and inhibition of the mitochondrial respiratory chain will increase incorporation of α-synuclein into the aggregates in vitro.
25 Finally, deficits in energy metabolism have been proposed as a primary pathogenic mechanism in Huntington’s disease, with elevated lactate levels being detected in the occipital cortex and basal ganglia.
26 Ultrastructural analyses have demonstrated that mutant huntingtin appears to be present on neuronal mitochondrial membranes
27 and can directly increase mitochondrial susceptibility to calcium-induced permeability transition, resulting in the release of cytochrome
c.
28 These studies are consistent with the mechanisms that might be involved in CryAB
R120G pathogenesis, as our data show that CryAB
R120G expression leads to detectable amyloid formation in the cardiomyocytes
8 and mitochondrial dysfunction, which, in turn, could contribute to a more rapid amyloid accumulation and an inherently unstable feed-forward loop.
The release of cytochrome
c is a well-defined mechanism for activation of apoptosis and, in the last few years, the potential importance of apoptosis in heart failure has been defined.
29–32 Wencker established a causal role by showing that very low levels of myocyte apoptosis were sufficient to cause a lethal, dilated cardiomyopathy.
31 In a retrospective study on 33 patients who had died of acute myocarditis, cardiomyocyte apoptosis was identified as a common mechanism of myocardial damage with significantly more apoptotic cardiomyocytes present in patients who had died from progressive heart failure compared with those who died suddenly from cardiac arrest.
33 Cardiomyocytes transfected with CryAB
R120G show striking activation of both early and late apoptotic markers, confirming the potential of an acute response upon mutant CryAB expression. Significantly, we also found high levels of activated caspase-3 in the CryAB
R120G Tg hearts in the later disease stages of progressive heart failure (). Taking into consideration that the progression of cardiomyopathy and heart failure in CryAB
R120G mice occurs over a 5–7 month period, our model underscores the potential importance of apoptosis in progressive heart failure.
Our data point to the importance of a progressive pathology in the development of heart failure. It is clear that expression of CryABR120G has acute effects on cardiomyocyte mechanics, affecting contractility through as yet undefined mechanisms, although the accumulating aggregates could certainly play a physical role in attenuating normal cardiomyocyte contractile behavior. Alterations in contractility can be sensed by multiple mechanisms, resulting in global responses at the transcriptional and translational levels but we believe that a crucial aspect of the early pathology is linked to alterations in respiration. Mitochondria-sarcomere architecture is affected very early and complex I activity is significantly attenuated with reductions of 50% by 6 weeks, before alterations in cardiac function can be detected. This is rapidly followed by compromised PTP function and mitochondrial swelling. These become more severe over a period of 2–3 months, eventually leading to release of cytochrome c and activation of apoptosis.